Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Iraj Hasan, Lauren Parsons, Sabrina Duran, Zachary Zinn
BACKGROUND: Dupilumab, a human monoclonal antibody targeting the IL4 alpha receptor, is used for treatment of moderate to severe atopic dermatitis (AD). Previous studies have reported diagnoses of cutaneous T cell lymphoma (CTCL) after dupilumab use. OBJECTIVE: Investigate the risk of CTCL after dupilumab use in patients with AD. METHODS: Using the TrinetX database, incidence of cutaneous and lymphoid malignancies including CTCL was compared between a cohort of patients with AD who used dupilumab and a cohort of patients with AD who never used dupilumab...
April 6, 2024: Journal of the American Academy of Dermatology
#22
JOURNAL ARTICLE
Bronwyn D Power, Rangi Kandane-Rathnayake, Georgina Tiller, William D Renton, Angela Cox, Lilian Johnstone, Alberta Hoi, Peter Gowdie
INTRODUCTION: We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and to describe the enrolment data with a focus on clinical characteristics, serological data, treatment strategies and patient/parent-reported outcome measures. METHODS: All patients under the age of 18 years with a diagnosis of systemic lupus erythematosus (SLE) attending the paediatric rheumatology service of a single, tertiary hospital were identified...
April 8, 2024: Lupus
#23
JOURNAL ARTICLE
Elise van Mulligen
No abstract text is available yet for this article.
April 4, 2024: Lancet Rheumatology
#24
JOURNAL ARTICLE
Kaja E Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge C Olsen, Hallvard Fremstad, Cristina Spada, Tor Magne Madland, Christian A Høili, Gunnstein Bakland, Åse Lexberg, Inger Johanne Widding Hansen, Inger Myrnes Hansen, Hilde Haukeland, Maud-Kristine Aga Ljoså, Ellen Moholt, Till Uhlig, Tore K Kvien, Daniel H Solomon, Désirée van der Heijde, Espen A Haavardsholm, Siri Lillegraven
BACKGROUND: Tapering of disease-modifying antirheumatic drugs (DMARDs) to drug-free remission is an attractive treatment goal for patients with rheumatoid arthritis, although long-term effects of tapering and withdrawal remain unclear. We compared 3-year risks of flare between three conventional synthetic DMARD treatment strategies in patients with rheumatoid arthritis in sustained remission. METHODS: In this open-label, randomised controlled, non-inferiority trial, we enrolled patients aged 18-80 years with rheumatoid arthritis who had been in sustained remission for at least 1 year on stable conventional synthetic DMARD therapy...
April 4, 2024: Lancet Rheumatology
#25
REVIEW
Yasaman Hajiesmaeili, Preeti Tamhankar, Saverio Stranges, Lillian Barra
INTRODUCTION: Rheumatoid arthritis (RA) is the most common form of autoimmune inflammatory arthritis and is associated with various comorbidities including cardiovascular disease (CVD). This scoping review summarizes the current evidence on longitudinal cohort studies assessing potential factors associated with the incidence of cardiovascular events among patients with RA. METHODS: Scopus, PubMed, Ovid MEDLINE and Cochrane databases were used to identify longitudinal cohort studies investigating the incidence of CVD among RA patients...
April 4, 2024: Autoimmunity Reviews
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 4, 2024: RMD Open
#27
JOURNAL ARTICLE
Tatjana Rudi, Vera Zietemann, Yvette Meissner, Angela Zink, Andreas Krause, Hanns-Martin Lorenz, Christian Kneitz, Martin Schaefer, Anja Strangfeld
OBJECTIVES: To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD). METHODS: Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression, the association between clinical measures and mortality was investigated...
April 4, 2024: RMD Open
#28
JOURNAL ARTICLE
Kevin Windirsch, Suzana Jordan, Mike Oliver Becker, Cosimo Bruni, Rucsandra Dobrota, Muriel Elhai, Ion-Alexandru Garaiman, Carmen-Marina Mihai, Michele Iudici, Paul Hasler, Camillo Ribi, Britta Maurer, Armando Gabrielli, Anna-Maria Hoffmann-Vold, Oliver Distler
OBJECTIVES: Systemic sclerosis is a chronic autoimmune connective tissue disease leading to microvascular and fibrotic manifestations in multiple organs. Several treatment options and recommendations from different European countries are available. In this study, for which the ambit is Switzerland specifically, we aim to describe the treatment patterns of systemic sclerosis patients with fibrotic manifestations. METHODS: Systemic sclerosis patients were selected from six Swiss tertiary centres recorded in the multicentre, prospective European Scleroderma Trials and Research (EUSTAR) registry...
February 6, 2024: Swiss Medical Weekly
#29
JOURNAL ARTICLE
Xue Meng, Ang Lv, Mulin Tang, Xue Liu, Xinhui Wang, Yuchen Li, Yuwei Chai, Qingqing Yang, Chunjia Kou, Li Zhang, Ming Li, Haiqing Zhang
OBJECTIVE: To identify risk factors for the development of non-thyroidal illness syndrome (NTIS) in patients with systemic lupus erythematosus (SLE). METHODS: A retrospective analysis of 517 SLE patients and 1034 age-and sex-matched healthy population was conducted to compare the prevalence of NTIS in these two groups, and to analyze the laboratory and clinical characteristics of SLE patients with NTIS. Finally Logistic regression analysis was used to determine the risk factors for NTIS in SLE patients...
April 5, 2024: Clinical Rheumatology
#30
JOURNAL ARTICLE
Maximilian Casey, Sonia Pannu, Saffia Bajwa, Alí Duarte-García, Michael Putman
BACKGROUND: Neuroinflammatory adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to date have compared the real-world risk of TNFs to other new users of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARD). The objective of this study is to describe the risk of neuroinflammatory disease after initiation b/tsDMARDs. METHODS: This new-user comparative effectiveness cohort study utilized a large US-based electronic health-records database to describe the unadjusted incidence of neuroinflammatory adverse events over a 3-year period...
April 3, 2024: Arthritis Care & Research
#31
JOURNAL ARTICLE
Durga Prasanna Misra, Upendra Rathore, Swapnil Jagtap, Prabhaker Mishra, Darpan R Thakare, Kritika Singh, Tooba Qamar, Deeksha Singh, Juhi Dixit, Manas Ranjan Behera, Neeraj Jain, Manish Ora, Dharmendra Singh Bhadauria, Sanjay Gambhir, Vikas Agarwal, Sudeep Kumar
OBJECTIVE: To describe the incidence, risk factors, and outcomes associated with serious infections in patients with Takayasu arteritis (TAK). METHODS: Serious infections (defined as infections resulting in hospitalization or death or unusual infections like tuberculosis) were identified from a cohort of patients with TAK. Corticosteroids and disease-modifying anti-rheumatic drug (DMARD) use at the time of serious infection was noted. Demographic characteristics, clinical presentation, angiography, and disease activity at presentation and the use of DMARDs during follow-up were compared between patients with TAK with or without serious infections...
April 1, 2024: Journal of Rheumatology
#32
JOURNAL ARTICLE
Daniel G Fernández-Ávila, Wilson Bautista-Molano, María Lorena Brance, María Gabriela Ávila Pedretti, Rubén Burgos Vargas, José Francisco Díaz Coto, Luis Arturo Gutiérrez, Marwin Gutiérrez, Enrique Giraldo Ho, Sebastián Eduardo Ibáñez Vodnizza, Edwin Jáuregui, Vanessa Ocampo, Penélope Esther Palominos, Daniel Ruben Palleiro Rivero, Guillermo Andrés Quiceno, Fernando Andrés Sommerfleck, Luis Enrique Vega Espinoza, Oscar Vega Hinojosa, Claudia Vera Barrezueta, Inés Corbacho, Vanesa Laura Cosentino, Annelise Goecke Sariego, Gustavo Gomes Resende, Lina María Saldarriaga-Rivera, Cesar Francisco Pacheco Tena, Gustavo Citera, Carlos Lozada, Roberto Ranza, Percival D Sampaio-Barros, Emilce Schneeberger, Enrique R Soriano
OBJECTIVE: Psoriatic arthritis (PsA) is chronic disease that compromise multiple domains, and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective is to generate evidence-based recommendations on the management of PsA in PANLAR countries. METHODS: We used the Grading of Recommendations, Assessment, Development and Evaluation GRADEADOLOPMENT approach to adapt the 2019 recommendations of the European League Against Rheumatism (EULAR)...
April 1, 2024: Journal of Rheumatology
#33
JOURNAL ARTICLE
Ignacio Braña, Marta Loredo, Estefanía Pardo, Stefanie Burger, Eva Fernández-Bretón, Rubén Queiro
OBJECTIVE: Information on the persistence of tofacitinib in PsA is scarce in real-life conditions. Our objective was to analyze persistence and safety of tofacitinib under these conditions. METHODS: Single-center retrospective longitudinal observational study of all PsA patients that received at least one dose of tofacitinib. Main focus was on adverse events and drug survival. Drug survival was analyzed by Kaplan-Meier curves and persistence explanatory factors by multivariate Cox regression models...
April 1, 2024: Journal of Rheumatology
#34
JOURNAL ARTICLE
Mahir Bhardwaj, Dilpreet Kour, Garima Rai, Srija Bhattacharya, Diksha Manhas, Bhavna Vij, Ajay Kumar, Debaraj Mukherjee, Zabeer Ahmed, Sumit G Gandhi, Utpal Nandi
EIDD-1931 is the active form of molnupiravir, an orally effective drug approved by the United States Food and Drug Administration (USFDA) against COVID-19. Pharmacokinetic alteration can cause untoward drug interaction (drug-drug/disease-drug), but hardly any information is known about this recently approved drug. Therefore, we first investigated the impact of the arthritis state on the oral pharmacokinetics of EIDD-1931 using a widely accepted complete Freund's adjuvant (CFA)-induced rat model of rheumatoid arthritis (RA) after ascertaining the disease occurrence by paw swelling measurement and X-ray examination...
March 26, 2024: ACS Omega
#35
Ezgi Akyildiz Tezcan, Kemal Erol, Ilknur Albayrak Gezer
Piriformis syndrome is a neuromuscular disorder characterized by hip, buttock, and leg pain. Axial spondyloarthritis is a rheumatic disease primarily affecting the sacroiliac joint and the spine. Due to their anatomical proximity, the potential relationship between piriformis syndrome and sacroiliitis has been discussed for some time. However, literature review revealed that there is no study on piriformis syndrome in individuals with axial spondyloarthritis. Here, we present the case of a 30-year-old female with axial spondyloarthritis who developed severe low back, hip, and buttock pain that persisted despite initial treatment for axial spondyloarthritis...
April 1, 2024: Journal of rheumatic diseases
#36
REVIEW
Lili Balogh, Katalin Oláh, Soma Sánta, Nóra Majerhoffer, Tamás Németh
Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a significant portion of the population with an increasing rate of incidence, which means that is essential to have effective therapies to control these chronic disorders. Unfortunately, several patients with systemic autoimmune diseases do not respond at all or just partially respond to available conventional synthetic disease-modifying antirheumatic drugs and targeted therapies...
2024: Frontiers in Immunology
#37
JOURNAL ARTICLE
Merve Cansu Polat, Elif Çelikel, Zahide Ekici Tekin, Tuba Kurt, Melike Mehveş Kaplan, Vildan Güngörer, Nilüfer Tekgöz, Müge Sezer, Cüneyt Karagöl, Serkan Coşkun, Nimet Öner, Serdar Sezer, Banu Çelikel Acar
UNLABELLED: The purpose of this study was to compare the demographic and clinical characteristics of the groups with and without bDMARDs added to the treatment of persistent oligoarticular juvenile idiopathic arthritis (JIA) patients on methotrexate (MTX) and also to determine the predictors of adding bDMARDs to treatment. This study included 86 oligoarticular JIA patients on MTX. Patients were divided into two groups receiving MTX (n = 69) and MTX plus bDMARD (n = 17)...
March 30, 2024: European Journal of Pediatrics
#38
JOURNAL ARTICLE
Alexandros Panagiotopoulos, George E Fragoulis, Aikaterini Arida, Vassiliki-Kalliopi Bournia, Gerasimos Evangelatos, Kalliopi Fragkiadaki, Evrydiki Kravvariti, Katerina Laskari, Maria Mylona, Nikolaos Michalakeas, Nikolaos Papazoglou, Maria Pappa, Vassiliki Poulia, Stylianos Panopoulos, Sevastiani Ziarangali, Vasileios Papatheodorou, Maria G Tektonidou, Petros P Sfikakis
Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least one COVID-19 re-infection (mean age 47.3 years, females 70.7%). SRD patients were compared in terms of patient-perceived COVID-19 re-infection severity and hospitalizations/deaths with 167 age/sex-matched non-SRD controls...
March 29, 2024: Rheumatology International
#39
REVIEW
Fabiola A Chapa-Villarreal, Madeleine Stephens, Rachel Pavlicin, Micaela Beussman, Nicholas A Peppas
Rheumatoid arthritis (RA) is an autoimmune disease suffered by millions of people worldwide. It can significantly affect the patient's quality of life by damaging not only the joints but also organs such as the lungs and the heart. RA is normally treated using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologics. These active agents often cause side effects and offer low efficacy due to their lack of specificity and limited retention time...
May 2024: Advanced Drug Delivery Reviews
#40
JOURNAL ARTICLE
Pål Nicolay Fougner Rydning, Hege Linnerud, Jalal Mirzamohammadi, Tor Brommeland, Pål Andre Rønning, Magnus Evjensvold, Mads Aarhus, Gunnstein Bakland, Eirik Helseth
BACKGROUND CONTEXT: Individuals diagnosed with ankylosing spondylitis (AS) face an increased risk of spine fractures, specifically cervical spine fractures (CS-Fxs). In the past two decades, biological disease-modifying antirheumatic drugs (bDMARDs) have provided considerable relief from pain and an enhanced sense of wellbeing for a large segment of AS patients. Despite these improvements, it remains unclear whether extended use of bDMARDs can indeed reduce the risk of spine fractures...
March 26, 2024: Spine Journal: Official Journal of the North American Spine Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
